|
Ohr completes wet–AMD trial enrollment
ModernMedicine New York—Ohr Pharmaceuticals has completed the enrollment of its OHR-022 phase II clinical trial evaluating its treatment of we age-related macular degeneration (AMD), Squalamine eye drops. The study has enrolled 142 patients, and the company … |
Source: Wet Macular Degeneration News From Google News
Zennie Abraham | Zennie Abraham or “Zennie62” is the founder of Zennie62Media which consists of zennie62blog.com and a multimedia blog news aggregator and video network, and 78-blog network, with social media and content development services and consulting. Zennie is a pioneer video blogger, YouTube Partner, social media practitioner, game developer, and pundit. Note: news aggregator content does not reflect the personal views of Mr. Abraham.